Monday, 28 May 2018

You are here

Prevention of HBV Infection: How Are We Doing?

Hepatitis B virus (HBV) infection remains a large cause of morbidity and mortality in worldwide despite it being preventable through screening and vaccination.

In 2016, WHO set out to eliminate HBV infection as a public health threat by 2030. We are far from this goal. Vaccine implementation has been suboptimal in a number of important patient populations, including patients with rheumatologic diseases, as well as other immunocompromising diseases like HIV.

Screening and vaccinating such populations is of utmost importance because hepatitis B surface antigen (HBsAg – chronic infection) and even core antibody (HBcAb – resolved infection) positive patients are at risk of reactivating infection in the setting of immunosuppression, in particular rituximab.

In 2010, survey data was published in Arthritis Care and Research authors queried 1,000 rheumatologists nationwide about familiarity with published guidelines for hepatitis B screening and their awareness of risk of HBV reactivation. While response rate was low they found that depending on the drug 19-53% of physicians were aware of the package insert warning re: HBV reactivation, 42% routinely screened for HBV reactivation prior to starting DMARDs and 69% before biologics. This article is 7 years old but I do not doubt that these low numbers still ring true. (https://buff.ly/2mJ6ftw)

A study published in the Annals of Internal medicine in December 2017 sought to estimate the prevalence of hepatitis B vaccination among U.S. patients with HIV in 2009 through 2012. Out of 18,000 they found that over 1/3 of these patients had missed opportunities to initiation the vaccine series. (https://buff.ly/2DKiPkr)

The current CDC/ACP recommendations state that clinicians should vaccinate all unvaccinated adults at risk including at risk by sexual exposure, percutaneous or mucosal exposure (e.g. healthcare workers), chronic liver disease, ESRD and HIV infection.

While patients requiring immunosuppression are not included here, they are recommended for screening (with HBsAg, HBcAb and HBsAb). What are the ACR guidelines for screening for HBV? They are not exactly clear.

They recommend screening “high-risk” patients receiving leflunomide or methotrexate, and that appropriate evaluation “might include” HBsAg, HBsAb and HbcAb. They mention no recommendation to screen before starting biologics. 

With the growing use of immunosuppression, in particular biologics, we must be aware of the risk of HBV reactivation, which can lead to interruption of treatment and adverse liver consequences, all of which are largely preventable by timely screening and vaccination.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.

MMWR: Cannabis Use in the Colorado Workers

MMWR reports that eight states, including Colorado, have legalized recreational marijuana for use by adults and that a study of use in Colorado has shown that nearly 15% of Colorado adult workers have used marijuana in the past 30 days. Use was highest among young adults, especially men, working in the Accommodation/Food Services and Food Preparation/Serving industries.

EMA to Review Methotrexate Overdose and Dosing Errors

A recent meeting (April 9-12) of the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) considered the problem of dosing errors with methotrexate (MTX), citing "continued reports of overdose." 

2 Weeks Off Methotrexate OK for Flu Vaccine

Stopping methotrexate for 2 weeks after the administration of flu vaccine led to improved immunogenicity without increasing disease activity among patients with rheumatoid arthritis (RA), a prospective Korean study showed.

Risk of Paternal Exposure to Anti-Rheumatic Drugs

Seminars in Arthritis and Rheumatism features a review of the effects of paternal use of antirheumatic drugs on pregnancy, specifically addressing the effects of NSAIDs, steroids, DMARDs and biologics on spermatogenesis and the effect on pregnancy outcomes and offspring.